Selexis SA
Selexis SA is a Belgian life sciences company that develops and licenses the SUREtechnology Platform, a proprietary CHO-based cell line development system used by CDMOs and biopharmaceutical companies to produce stable mammalian cell lines for biologics manufacturing.
- Company typePrivate
- Founded2001
- HeadquartersLeuven, Belgium
- Headcount1,001–5,000
- GTM typeB2B
- OfferingSoftware
What Selexis SA does
Selexis SA is a Belgian life sciences company founded in 2001 and headquartered in Leuven that develops and licenses proprietary cell line development technology for biopharmaceutical manufacturing. Its core offering is the SUREtechnology Platform, a CHO-based cell line development system designed to produce stable, high-yield mammalian cell lines for therapeutic protein and complex biologics production. The platform is built on more than 30 years of cell line development expertise and is positioned as a versatile, scalable, and integrated solution spanning the drug development pipeline from clinical to commercial manufacturing.
The company operates a B2B technology licensing model rather than a direct service business. Selexis generates revenue by embedding its SUREtechnology Platform into the manufacturing workflows of contract development and manufacturing organizations (CDMOs) and biopharmaceutical companies, with disclosed revenue mechanics being licensing fees and royalties. Its most prominent disclosed partner is KBI Biopharma, which features the Selexis technology as a core component of its mammalian cell line development service offering. The company targets biopharmaceutical firms developing complex biologics, using a horizontal segmentation approach across the industry.
Pricing is not publicly disclosed. The source data does not provide headcount, revenue, funding history, ownership structure, or management team details, which limits financial and governance assessment. No AI/ML capabilities, regulatory milestones, M&A activity, or leadership changes are disclosed in the available data.
Selexis SA firmographics
Firmographics- Name
- Selexis SA
- Legal name
- Selexis SA
- Website
- https://selexis.com
- Company type
- Private
- Founded year
- 2001
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- Selexis SA is a Belgian life sciences company that develops and licenses the SUREtechnology Platform, a proprietary CHO-based cell line development system used by CDMOs and biopharmaceutical companies to produce stable mammalian cell lines for biologics manufacturing.
- Ownership category
- akta.pro rank
Selexis SA industry classification
Industry- Product category
- Cell Line Development Technology / Biopharmaceutical Platform Technology
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Services-Commercial Physical & Biological Research (8731), Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC)
- akta.pro secondary industry
- Drug Substance–Drug Product Integrated CDMO (HLAGABAG)
Keywords
Where Selexis SA is headquartered
LocationHeadquarters
- HQ city
- Leuven
- HQ country
- Belgium
- HQ region
- Europe
Markets served
Selexis SA business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Operations
Revenue model
- Technology Licensing: Selexis generates revenue through licensing its proprietary SUREtechnology Platform to biopharmaceutical companies and CDMOs. The technology is embedded into partners' manufacturing workflows, generating licensing fees and royalties.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels1 record
Selexis SA product offering
Product offeringCore offering
Selexis SA develops and licenses its proprietary SUREtechnology Platform, a CHO-based cell line development technology that enables biopharmaceutical companies and CDMOs to generate premium, stable, and integrated mammalian cell lines for the production of complex therapeutic proteins and biologics. The technology is embedded into partner CDMO manufacturing workflows, supporting cell line development from clinical stages through commercial manufacturing.
Product overview
Selexis SA provides proprietary cell line development technology that is licensed to and integrated into partner CDMOs (Contract Development and Manufacturing Organizations) such as KBI Biopharma. The Selexis® technology platform powers the SUREtechnology Platform™ used by KBI for mammalian cell line development services. The company operates as a technology provider rather than a direct service provider.
Differentiator
Problem solved
Functional benefit
Products and services
- SUREtechnology Platform (Selexis® Technology) Proprietary CHO-based cell line development technology platform that provides premium, stable, and integrated mammalian cell lines for the production of complex therapeutic proteins and biologics. Licensed to and embedded within CDMO and biopharmaceutical partner workflows (e.g., KBI Biopharma) to support cell line development from clinical stages through commercial manufacturing.
Companies that use Selexis SA
Customer profileSegments1 record
Ideal customer profiles2 records
Selexis SA technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Selexis SA partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- KBI BiopharmacoreSelexis provides its proprietary SUREtechnology Platform to KBI Biopharma, enabling the CDMO to offer premium, stable, and integrated CHO-based cell line development services. KBI Biopharma features the SUREtechnology Platform as a core component of its mammalian cell line development offerings, supporting the development and manufacturing of complex biologics.
Scale indicators1 record
Recent moves3 records
Expansion highlights1 record
Selexis SA competitors and assessment
Company assessmentMarket position
Competitive moat3 records
Key risks4 records
Key highlights5 records
Customer concentration
Selexis SA social profiles
Digital presenceSelexis SA financial estimates
Financial estimateRevenue estimate
Valuation estimate
Selexis SA leadership team
Management profileNumber of profiles
Selexis SA funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Selexis SA M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Selexis SA
What does Selexis SA do?
Selexis SA develops and licenses its proprietary SUREtechnology Platform, a CHO-based cell line development technology that enables biopharmaceutical companies and CDMOs to generate premium, stable, and integrated mammalian cell lines for the production of complex therapeutic proteins and biologics. The technology is embedded into partner CDMO manufacturing workflows, supporting cell line development from clinical stages through commercial manufacturing.
Is Selexis SA a public or private company?
Selexis SA is a private company. It is classified as unknown and is currently operating.
When was Selexis SA founded?
Selexis SA was founded in 2001. It employs 1,001 to 5,000 people.
Where is Selexis SA based?
Selexis SA is headquartered in Leuven, Belgium, in the Europe region.
How does Selexis SA make money?
One revenue line is on record: technology Licensing.
Does Selexis SA have an API?
No public API is recorded for Selexis SA.
What industry is Selexis SA in?
Selexis SA's product category is Cell Line Development Technology / Biopharmaceutical Platform Technology. Its primary akta.pro industry code is HLAGABAC, Biologics (mAbs/Recombinant Proteins) CDMO, with a secondary code of HLAGABAG, Drug Substance–Drug Product Integrated CDMO. Its NAICS code is 3254 and its SIC code is 8731.